These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 25128046

  • 1. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
    Kobelt G.
    Value Health; 2014 Jul; 17(5):537-44. PubMed ID: 25128046
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
    Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P.
    Int J Technol Assess Health Care; 2011 Jul; 27(3):193-200. PubMed ID: 21736857
    [Abstract] [Full Text] [Related]

  • 3. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 4. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A.
    Mod Rheumatol; 2006 Nov; 16(2):77-84. PubMed ID: 16633926
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G, Lindgren P, Singh A, Klareskog L.
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [Abstract] [Full Text] [Related]

  • 6. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.
    Int J Immunopathol Pharmacol; 2009 Aug; 22(4):1147-52. PubMed ID: 20074482
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ, Brennan A, Ghatnekar O.
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ.
    J Med Econ; 2012 Jul; 15(2):340-51. PubMed ID: 22168785
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR, Hay J.
    Pharmacoeconomics; 2006 Jul; 24(12):1221-32. PubMed ID: 17129076
    [Abstract] [Full Text] [Related]

  • 10. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A, Cifaldi MA, Segurado OG, Weisman MH.
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [Abstract] [Full Text] [Related]

  • 12. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.
    Pharmacoeconomics; 2012 Jul 01; 30(7):575-93. PubMed ID: 22640174
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S.
    Clin Exp Rheumatol; 2013 Jul 01; 31(3):400-8. PubMed ID: 23464803
    [Abstract] [Full Text] [Related]

  • 14. [Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study].
    Schulze-Koops H, Deeg M, Runge C, Volmer T, Brecht JG.
    Z Rheumatol; 2009 Dec 01; 68(10):836-41. PubMed ID: 19756664
    [Abstract] [Full Text] [Related]

  • 15. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B.
    Lancet; 2013 Mar 16; 381(9870):918-29. PubMed ID: 23332236
    [Abstract] [Full Text] [Related]

  • 16. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA, Plosker GL.
    Pharmacoeconomics; 2004 Mar 16; 22(16):1071-95. PubMed ID: 15524495
    [Abstract] [Full Text] [Related]

  • 17. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
    Kobelt G, Eberhardt K, Geborek P.
    Ann Rheum Dis; 2004 Jan 16; 63(1):4-10. PubMed ID: 14672883
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.
    Rheumatology (Oxford); 2015 Jul 16; 54(7):1226-35. PubMed ID: 25573840
    [Abstract] [Full Text] [Related]

  • 19. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B, Botsios C, Ometto F, Bernardi L, Stramare R, Todesco S, Sfriso P, Punzi L.
    Clin Exp Rheumatol; 2015 Jul 16; 33(1):63-8. PubMed ID: 25535985
    [Abstract] [Full Text] [Related]

  • 20. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars.
    Wu B, Song Y, Leng L, Bucala R, Lu LJ.
    Clin Exp Rheumatol; 2015 Jul 16; 33(1):20-6. PubMed ID: 25438197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.